SCHEMBL24974607

SCHEMBL24974607

COCC(C)(C)Cn1cc(-c2cccc(NC(=O)N3CCC4(CC3)NC(=O)N(c3ccccc3)C4=O)c2)nn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TACR1 P25103 1/20 0.40
▸ NAMPT P43490 3/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ POLB P06746 2/20 0.37
▸ TRPV1 Q8NER1 1/20 0.36
▸ HDAC3 O15379 2/20 0.36
▸ HDAC1 Q13547 2/20 0.36
▸ HDAC2 Q92769 2/20 0.36
▸ HDAC10 Q969S8 2/20 0.36
▸ HDAC8 Q9BY41 2/20 0.36
▸ HDAC6 Q9UBN7 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ UCHL5 Q9Y5K5 1/20 0.36
▸ KIT P10721 1/20 0.35
▸ ITGB3 P05106 1/20 0.35
▸ ITGA2B P08514 1/20 0.35
▸ KDR P35968 1/20 0.35
▸ CYP2C19 P33261 2/20 0.35
▸ TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24974733 0.87 TACR1 (0.35) TACR1NAMPTSMN1; SMN2ALDH1A1POLB
SCHEMBL24974366 0.86 KDM4E (0.42) TACR1NAMPTPOLBHDAC3HDAC1
SCHEMBL24974537 0.77 SMN1; SMN2 (0.33) TACR1SMN1; SMN2ALDH1A1POLBTSHR
SCHEMBL24974736 0.76 TACR1 (0.51) TACR1NAMPTPOLBHDAC3HDAC1
SCHEMBL24974639 0.75 SMN1; SMN2 (0.41) TACR1NAMPTSMN1; SMN2ALDH1A1HDAC3
SCHEMBL24974548 0.74 KMT2A (0.37) TACR1NAMPTPOLBKDM4EKDR
SCHEMBL21150858 0.73 NAMPT (0.36) NAMPTHDAC3HDAC1HDAC2HDAC10
SCHEMBL21150845 0.72 NAMPT (0.34) TACR1NAMPTHDAC3HDAC1HDAC2
SCHEMBL21151259 0.72 NAMPT (0.34) TACR1NAMPTALDH1A1HDAC3HDAC1
SCHEMBL21151783 0.71 NAMPT (0.33) TACR1NAMPTSMN1; SMN2HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11572370-B2 CD16A binding agents and uses thereof BIOHAVEN THERAPEUTICS LTD. (US) 2023-02-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11572370-B2 CD16A binding agents and uses thereof FCGR1A, FCGR2A, FCGR3B TACR1 76/4885NAMPT 1356/4885SMN1; SMN2 3020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback